Literature DB >> 21112550

Interference with the Jaffé method for creatinine following 5-aminolevulinic acid administration.

Harry Quon1, Craig E Grossman, Rebecca L King, Mary Putt, Keri Donaldson, Larry Kricka, Jarod Finlay, Timothy Zhu, Andrea Dimofte, Kelly Malloy, Keith A Cengel, Theresa M Busch.   

Abstract

BACKGROUND: The photosensitizer pro-drug 5-aminolevulinic acid (5-ALA) has been administered systemically for photodynamic therapy. Although several toxicities have been reported, nephrotoxicity has never been observed.
MATERIALS AND METHODS: Patients with head and neck mucosal dysplasia have been treated on a phase 1 study of escalating light doses in combination with 60mg/kg of oral 5-ALA. Serum creatinine was measured with the modified Jaffe method or an enzymatic method in the first 24h after 5-ALA. Interference by 5-ALA, as well as by its photosensitizing product protoporphyrin IX, was assessed.
RESULTS: Among 11 subjects enrolled to date, 9 of 11 had blood chemistries collected within the first 5h with 7 demonstrating significant grade 3 creatinine elevations (p=0.030). There was no additional evidence of compromised renal function or increased PDT-induced mucositis. Creatinine levels measured by the Jaffe assay increased linearly as a function of the ex vivo addition of ALA (p<0.0001). The exogenous addition of PpIX did not alter creatinine levels. ALA did not interfere with creatinine levels as measured by an enzymatic assay. A total of 4 of the 11 subjects had creatinine levels prospectively measured by both the Jaffe and the enzymatic assays. Only the Jaffe method demonstrated significant elevations as a function of time after ALA administration.
CONCLUSIONS: The transient increase in creatinine after systematic ALA can be attributed, in part, if not entirely, to interference of ALA in the Jaffe reaction. Alternative assays should be employed in situations calling for monitoring of kidney function after systemic ALA.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21112550      PMCID: PMC3598580          DOI: 10.1016/j.pdpdt.2010.07.008

Source DB:  PubMed          Journal:  Photodiagnosis Photodyn Ther        ISSN: 1572-1000            Impact factor:   3.631


  13 in total

1.  Plasma levels of protoporphyrin IX in humans after oral administration of 5-aminolevulinic acid.

Authors:  J Webber; D Kessel; D Fromm
Journal:  J Photochem Photobiol B       Date:  1997-01       Impact factor: 6.252

2.  5-Aminolevulinic acid photosensitization of dysplastic Barrett's esophagus: a pharmacokinetic study.

Authors:  R Ackroyd; N Brown; D Vernon; D Roberts; T Stephenson; S Marcus; C Stoddard; M Reed
Journal:  Photochem Photobiol       Date:  1999-10       Impact factor: 3.421

3.  Porphyrin bleaching and PDT-induced spectral changes are irradiance dependent in ALA-sensitized normal rat skin in vivo.

Authors:  J C Finlay; D L Conover; E L Hull; T H Foster
Journal:  Photochem Photobiol       Date:  2001-01       Impact factor: 3.421

4.  Aminolevulinic acid (Levulan) in photodynamic therapy of actinic keratoses.

Authors:  K Lang; K W Schulte; T Ruzicka; C Fritsch
Journal:  Skin Therapy Lett       Date:  2001-09

5.  Correction of glucose concentration interference on Jaffé kinetic creatinine assay in peritoneal dialysis.

Authors:  G Da Rin; G Amici; G Virga; C Bardin; P Calzavara; C Bocci
Journal:  Am J Nephrol       Date:  1995       Impact factor: 3.754

6.  Side effects and photosensitization of human tissues after aminolevulinic acid.

Authors:  J Webber; D Kessel; D Fromm
Journal:  J Surg Res       Date:  1997-02-15       Impact factor: 2.192

Review 7.  ALA and its clinical impact, from bench to bedside.

Authors:  Barbara Krammer; Kristjan Plaetzer
Journal:  Photochem Photobiol Sci       Date:  2007-12-07       Impact factor: 3.982

8.  Photosensitisation and photodynamic therapy of oesophageal, duodenal, and colorectal tumours using 5 aminolaevulinic acid induced protoporphyrin IX--a pilot study.

Authors:  J Regula; A J MacRobert; A Gorchein; G A Buonaccorsi; S M Thorpe; G M Spencer; A R Hatfield; S G Bown
Journal:  Gut       Date:  1995-01       Impact factor: 23.059

9.  5-Aminolaevulinic acid-induced protoporphyrin IX accumulation in tissues: pharmacokinetics after oral or intravenous administration.

Authors:  J van den Boogert; R van Hillegersberg; F W de Rooij; R W de Bruin; A Edixhoven-Bosdijk; A B Houtsmuller; P D Siersema; J H Wilson; H W Tilanus
Journal:  J Photochem Photobiol B       Date:  1998-06-15       Impact factor: 6.252

10.  Catecholamine interference in enzymatic creatinine assays.

Authors:  Amy K Saenger; Christina Lockwood; Christine L Snozek; Thomas C Milz; Brad S Karon; Mitchell G Scott; Allan S Jaffe
Journal:  Clin Chem       Date:  2009-07-09       Impact factor: 8.327

View more
  2 in total

1.  Toxicities and early outcomes in a phase 1 trial of photodynamic therapy for premalignant and early stage head and neck tumors.

Authors:  Peter H Ahn; Harry Quon; Bert W O'Malley; Gregory Weinstein; Ara Chalian; Kelly Malloy; Joshua H Atkins; Thomas Sollecito; Martin Greenberg; Sally McNulty; Alexander Lin; Timothy C Zhu; Jarod C Finlay; Keith Cengel; Virginia Livolsi; Michael Feldman; Rosemarie Mick; Theresa M Busch
Journal:  Oral Oncol       Date:  2016-02-08       Impact factor: 5.337

Review 2.  Individualizing pharmacotherapy in patients with renal impairment: the validity of the Modification of Diet in Renal Disease formula in specific patient populations with a glomerular filtration rate below 60 ml/min. A systematic review.

Authors:  Willemijn L Eppenga; Cornelis Kramers; Hieronymus J Derijks; Michel Wensing; Jack F M Wetzels; Peter A G M De Smet
Journal:  PLoS One       Date:  2015-03-05       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.